Alaunos Therapeutics(US:TCRT)2022-11-14 19:10Financial Data and Key Metrics Changes - For Q3 2022, Alaunos reported a net loss of approximately $8.9 million or $0.04 net loss per share, compared to a net loss of approximately $22.7 million or $0.11 net loss per share for Q3 2021, indicating a significant reduction in losses [76]. - Collaboration revenue increased to approximately $2.9 million for Q3 2022, up from approximately $0.4 million in Q3 2021, primarily due to sales-based milestones achieved in Japan [77]. - Research and development expenses decreased by 46% to approximately $7.9 million in Q3 2022 from approximately $14.5 million in Q3 2021, attributed to lower program-related costs and reduced headcount [78]. - General and administrative expenses also saw a 60% decrease to approximately $3.3 million in Q3 2022 from approximately $8.2 million in the same period in 2021 [79]. - As of September 30, 2022, the company had approximately $37.8 million in cash and cash equivalents, with an operating cash burn of approximately $6.1 million for Q3 2022, down from approximately $9.6 million in Q3 2021 [80]. Business Line Data and Key Metrics Changes - The company is advancing its TCR-T Library Phase 1/2 trial, which targets hotspot mutations across six solid tumor indications, with ongoing patient enrollment at MD Anderson Cancer Center [18][45]. - The manufacturing suite has been updated to allow for simultaneous production of multiple products, increasing throughput capabilities [14][52]. Market Data and Key Metrics Changes - The company is focusing on solid tumors, specifically targeting KRAS, TP53, and EGFR mutations, which are prevalent in various cancers [73][74]. - The early clinical data presented at the CICON 2022 conference highlighted the first confirmed partial response using a non-viral TCR-T cell therapy in a solid tumor, generating increased interest from clinicians and patients [22][45]. Company Strategy and Development Direction - Alaunos aims to expand its TCR library by adding new TCRs targeting frequent mutations and HLAs, which will increase the addressable market for its therapy [85]. - The company plans to file an IND amendment to transition from fresh to cryopreserved TCR-T cell products, which is expected to enhance patient scheduling flexibility and reduce manufacturing time [86]. - The development of the membrane-bound IL-15 program is also underway, with an IND filing anticipated in the second half of 2023 [88]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early clinical data and the potential of the TCR-T cell therapy to treat solid tumors effectively, with expectations for increased patient enrollment in 2023 [90][91]. - The company is exploring various financing options to extend its cash runway into the second quarter of 2023, with interest from both existing and new investors [100][101]. Other Important Information - The company has successfully produced high-quality TCR-T cells at clinical scale and has demonstrated the ability to manufacture products for both KRAS and TP53 mutations [44][48]. - The persistence of TCR-T cells was observed in patients, indicating the potential for durable responses in the clinical setting [43]. Q&A Session Summary Question: Why is there a delay in dosing the next patient? - Management noted that the excitement from early data has built momentum for enrollment, and the addition of new TCRs will expand the patient funnel [95]. Question: What is the cash runway and financing options? - The cash runway extends into the second quarter of 2023, with various financing options available, including an ATM and shelf registration [100][101]. Question: Will the next patient be dosed at the same level as the previous one? - The next patient will be treated at the second dose level, which ranges from approximately 10 billion to 70 billion TCR-T cells [118]. Question: What are the expected tumor types for the next patient? - The specific tumor types for the next patient have not been disclosed, but they will be within the existing focus on KRAS, TP53, and EGFR mutations [120].